IDM says study shows Collidem vaccine well-tolerated for treatment of colorectal cancer

By Lisa Kerner

Erie, Pa., Jan. 30 - IDM Pharma, Inc. said its Collidem vaccine met its end point in a phase 1 trial, demonstrating to be a well-tolerated treatment with the induction of immune responses in patients with advanced colorectal cancer. Only mild injection site reactions were reported.

CD8 antigen specific responses were observed in a subset of patients and could be detected in both direct and restimulation assays, according to a company news release.

The company completed a phase 1 trial with colorectal cancer patients who had failed standard therapies. The patients were vaccinated with dendritic cells (made from the patient's own blood leukocytes). The cells were loaded with a cocktail of immunogenic peptides (epitopes) derived from tumor antigens, the company said.

About 145,900 new colorectal cancer cases were expected in the United States in 2005 with an estimated 56,920 deaths from the disease. The five-year relative survival rate of patients with distant stage advanced disease is only 10%.

The results were presented by researchers from the University of California at San Francisco at the 2006 ASCO Gastrointestinal Cancers Symposium.

San Diego-based IDM Pharma is a biopharmaceutical company focused on the development of innovative products that activate the immune system to treat cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.